Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) EPS (Basic) (2020 - 2026)

BioScience Health Innovations has reported EPS (Basic) over the past 7 years, most recently at -$0.02 for Q1 2026.

  • Quarterly EPS (Basic) fell 300.0% to -$0.02 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.03 through Mar 2026, down 250.0% year-over-year, with the annual reading at $0.06 for FY2025, 500.0% up from the prior year.
  • EPS (Basic) was -$0.02 for Q1 2026 at BioScience Health Innovations, roughly flat from -$0.02 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.01 in Q3 2024 and troughed at -$0.02 in Q4 2025.
  • The 5-year median for EPS (Basic) is -$0.0 (2023), against an average of -$0.0.
  • Year-over-year, EPS (Basic) plummeted 1392.18% in 2022 and then soared 875.4% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.01 in 2022, then skyrocketed by 78.53% to -$0.0 in 2023, then plummeted by 343.67% to -$0.01 in 2024, then tumbled by 296.61% to -$0.02 in 2025, then increased by 0.0% to -$0.02 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's EPS (Basic) are -$0.02 (Q1 2026), -$0.02 (Q4 2025), and -$0.0 (Q3 2025).